Literature DB >> 21252025

Substitution of ethanol with specially designed microspheres in a TASH procedure.

George Latsios1, Ulrich Gerckens, Ralf Mueller, Eberhard Grube.   

Abstract

AIMS: We present our first clinical experience to substitute ethanol with special designed microspheres in a TASH procedure (transcatheter ablation of septal hypertrophy). TASH is a standard approach for the treatment of patients with hypertrophic obstructive cardiomyopathy, severely symptomatic despite maximal medical therapy. However, the injection of alcohol remains a source of some possible complications. METHODS AND
RESULTS: We substituted alcohol with special designed microspheres. A highly symptomatic HOCM patient underwent a procedure of percutaneous ablation of his hypertrophied septum with the use of Embozene microspheres. The procedure was successful, as the gradient was reduced from 70 before the procedure to 10 mmHg afterwards.
CONCLUSIONS: TASH by means of microspheres embolisation instead of alcohol was a safe and successful in the short-term procedure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252025     DOI: 10.4244/EIJV6I7A151

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  3 in total

1.  Cardiac tamponade due to coronary perforation during percutaneous interventions successfully treated with microspheres.

Authors:  Felix Meincke; Karl-Heinz Kuck; Martin W Bergmann
Journal:  Clin Res Cardiol       Date:  2014-01-08       Impact factor: 5.460

Review 2.  Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Angelos G Rigopoulos; Hubert Seggewiss
Journal:  Curr Cardiol Rev       Date:  2016

3.  Microsphere embolisation as an alternative for alcohol in percutaneous transluminal septal myocardial ablation.

Authors:  P A Vriesendorp; N M Van Mieghem; W B Vletter; F J Ten Cate; P L de Jong; A F L Schinkel; M Michels
Journal:  Neth Heart J       Date:  2013-05       Impact factor: 2.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.